Connect with us

Press Releases

Nemus Bioscience Signs Agreement with Albany Molecular Research to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma

mm

Published

on

(PRESS RELEASE) LONG BEACH, CA – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced an agreement with Albany Molecular Research Inc. for the development and manufacture of Nemus’ proprietary cannabinoid-based active pharmaceutical ingredients (API). The agreement will capitalize on AMRI’s process chemistry expertise in the synthesis and formulation of Nemus’ proprietary prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, Nemus’ compound in development for the treatment of glaucoma.

“Advancing our lead therapeutic candidates into the API manufacturing stage is a major milestone for our company and is pivotal for initiating human studies,” commented Brian Murphy, M.D., CEO-CMO of Nemus. “Cannabinoid-based therapies have the potential to revolutionize glaucoma therapy by not only lowering intraocular pressure, but by exerting a direct neuroprotective effect on the cells of the optic nerve, thereby preserving vision.” 

“AMRI looks forward to working with Nemus to bring this new class of cannabinoid-based therapies through the developmental process,” said Christopher Conway, Senior Vice President of Discovery and Development Services at AMRI. “AMRI will focus on manufacturing synthetic versions of Nemus’ proprietary prodrug of THC at our U.S. Drug Enforcement Administration (DEA) approved facilities.”

SPONSORED VIDEO

SPONSORED BY WEAVE

Transform Your Multi-office Phone System Into a Revenue-generation Tool

Weave’s multi-office, multi-department, and multi-provider phone system is built to flexibly accommodate and augment your practices’ most powerful revenue-generation tool: ring phones across multiple locations, set up inter-office call overflow, support external call centers, and more. And by connecting to your patient data, call handlers see a patient’s upcoming appointments, overdue balances, overdue family members, and preferred location – all when they pick up the phone." Learn more at getweave.com/weave-unify

Promoted Headlines

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular